Optimising drug delivery nanocarriers for clinical use
Recent years have witnessed an expansion of nanotechnology-based drug delivery carriers. However, lack of information on the various structural and biological features of these nanocarriers has limited their therapeutic applications. To address this, the EU-funded MANTARGET project is optimising the physicochemical properties such as size, shape and surface chemistry of biodegradable nanocarriers suitable for clinical applications. The idea is to develop nanocarriers capable of targeting mannose-6-phosphate receptors, which are over-expressed in prostate cancer, and determine their cell specificity, interaction and degradation following intracellular internalisation, through super-resolution microscopy (STORM). Moreover, studying the toxicity of these nanocarriers is significant prior to their clinical application in delivering chemotherapeutic drugs to cancer cells.